We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and... Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies. Show more
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments PR Newswire PLYMOUTH MEETING, Pa., Jan. 9, 2025 PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:...
INOVIO Announces Pricing of $30 Million Public Offering PR Newswire PLYMOUTH MEETING, Pa., Dec. 13, 2024 PLYMOUTH MEETING, Pa., Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq:...
INOVIO Announces Proposed Public Offering PR Newswire PLYMOUTH MEETING, Pa., Dec. 12, 2024 PLYMOUTH MEETING, Pa., Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a...
New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial PR Newswire PLYMOUTH MEETING...
INOVIO Reports Inducement Grant Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., Nov. 29, 2024 PLYMOUTH MEETING, Pa., Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...
INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PLYMOUTH MEETING, Pa., Nov. 14, 2024 New immunology data for INO-3107 supporting proposed mechanism...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.05 | 2.46305418719 | 2.03 | 2.1001 | 1.81 | 762364 | 1.90893768 | CS |
4 | 0.25 | 13.6612021858 | 1.83 | 2.39 | 1.75 | 1242763 | 1.98200549 | CS |
12 | -3.6 | -63.3802816901 | 5.68 | 5.8 | 1.74 | 942289 | 2.72957314 | CS |
26 | -8.98 | -81.1934900542 | 11.06 | 12.33 | 1.74 | 590026 | 4.07167547 | CS |
52 | -6.464 | -75.6554307116 | 8.544 | 14.748 | 1.74 | 593610 | 6.55287075 | CS |
156 | -53.84 | -96.2804005722 | 55.92 | 56.1 | 1.74 | 3890434 | 17.92926453 | CS |
260 | -39.2 | -94.9612403101 | 41.28 | 426 | 1.74 | 9155111 | 122.26095195 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions